Crowley, Stephanie J <br/><br/>
Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH.  [electronic resource] 

 -  Open biology  02 2020 
 - 190235 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>2046-2441 
<br/><br/><label>Standard No.: </label>10.1098/rsob.190235  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antigens, Neoplasm--immunology<br/>Autoantigens--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Camelids, New World--immunology<br/>Cancer Vaccines--administration & dosage<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Histocompatibility Antigens Class II--immunology<br/>Interleukin-2--administration & dosage<br/>Melanoma--drug therapy<br/>Mice<br/>Peptides--administration & dosage<br/>Recombinant Proteins--administration & dosage<br/>Single-Domain Antibodies--metabolism<br/>Vaccines, Subunit<br/>Xenograft Model Antitumor Assays